ClinicalTrials.Veeva

Menu
F

FACET Dermatology | Toronto, Canada

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Rocatinlimab
Guselkumab
LY3454738
NAV-240
Camoteskimab
Lebrikizumab
Lutikizumab
Ritlecitinib
Deuruxolitinib
JNJ-77242113

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 17 total trials

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

The purpose of this study is to learn about the safety and effects of the study medicine (called Ritlecitinib) for the possible treatment of hidraden...

Active, not recruiting
Hidradenitis Suppurativa
Drug: Ritlecitinib
Drug: Placebo

This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.

Enrolling
Atopic Dermatitis
Eczema Atopic Dermatitis
Drug: Camoteskimab
Drug: Placebo

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Active, not recruiting
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in ar...

Active, not recruiting
Hidradenitis Suppurativa
Drug: Placebo
Drug: Lutikizumab

The main objective of this study is to determine if NAV-240 works more effectively than a dummy treatment (placebo) for participants with moderate-to...

Enrolling
Hidradenitis Suppurativa (HS)
Drug: Placebo to match NAV-240
Drug: NAV-240

The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to \<18 Years Old) with moderate at...

Active, not recruiting
Atopic Dermatitis
Drug: Vehicle Cream
Drug: Ruxolitinib

This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair l...

Enrolling
Alopecia Areata
Drug: Placebo
Drug: Deuruxolitinib

Trial sponsors

Amgen logo
Janssen (J&J Innovative Medicine) logo
Lilly logo
AbbVie logo
A
Incyte logo
Pfizer logo
N
S

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems